• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ISONIAZID Drug Record

  • Summary
  • Interactions
  • Claims
  • ISONIAZID chembl:CHEMBL64 Approved

    Alternate Names:

    ISONICOTINYLHYDRAZINE
    RIMIFON
    NSC-9659
    STANOZIDE
    DOW-ISONIAZID
    NYDRAZID
    NICOTIBINE
    LANIAZID
    ISONIAZID
    HYZYD
    INH
    ISONICOTINOHYDRAZIDE
    ISONICOTINIC ACID HYDRAZIDE
    PYRIDINE-4-CARBOXYLIC ACID HYDRAZIDE
    ISONICOTINOYLHYDRAZIDE
    ISONICOTINIC HYDRAZIDE
    ISONICOTINSAEUREHYDRAZID
    4-PYRIDINECARBOHYDRAZIDE
    drugbank:00951
    chembl:CHEMBL64
    chemidplus:54-85-3
    rxcui:6038
    pubchem.compound:3767

    Drug Info:

    (0 More Sources)

    Publications:

    Fontana et al., 2005, Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity., Curr. Drug Metab.
    Chan SL et al., 2017, Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients., PLoS One
    Wu S et al., 2016, Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity., PLoS One
    He L et al., 2015, Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study., PLoS One
    Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Nanashima K et al., 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients., Tuberculosis (Edinb)
    Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
    Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
    Yimer G et al., 2011, Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients., PLoS One
    Cramer JP et al., 2010, Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation., Transpl Int
  • ISONIAZID   MAFK

    Interaction Score: 14.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 22341855


    Sources:
    PharmGKB

  • ISONIAZID   BACH1

    Interaction Score: 14.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 22341855


    Sources:
    PharmGKB

  • ISONIAZID   XPO1

    Interaction Score: 2.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 22341855


    Sources:
    PharmGKB

  • ISONIAZID   NOS2

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22341855


    Sources:
    PharmGKB

  • ISONIAZID   GSTP1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 27281183 25798582


    Sources:
    PharmGKB

  • ISONIAZID   CYP2B6

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387


    Sources:
    PharmGKB

  • ISONIAZID   TNF

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • ISONIAZID   ABCB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 22162992 19686464


    Sources:
    PharmGKB

  • ISONIAZID   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20941486 22931300


    Sources:
    DTC PharmGKB

  • ISONIAZID   NR1I2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISONIAZID   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16248836 22931300


    Sources:
    DTC

  • ISONIAZID   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16248836


    Sources:
    PharmGKB

  • ISONIAZID   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16248836


    Sources:
    DTC

  • DTC: ISONIAZID

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL64 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: isoniazid

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Nanashima K et al., 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients., Tuberculosis (Edinb)
    Chan SL et al., 2017, Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients., PLoS One
    Cramer JP et al., 2010, Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation., Transpl Int

  • TTD: Isoniazid

    • Version: 2020.06.01

    Alternate Names:
    D09XQF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL64

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21